Skip to main content

What the FDA labels say about taking them together

Medroxyprogesterone and tamoxifen

Tamoxifen's FDA label of December 18, 2025 names medroxyprogesterone in its drug interactions section; the medroxyprogesterone labels PlainMeds reads (3) do not name tamoxifen. The tamoxifen label: “Medroxyprogesterone reduces plasma concentrations of N-desmethyl, but not tamoxifen.”

Check it at the source: the medroxyprogesterone FDA label on DailyMed (effective June 29, 2026, Pharmacia & Upjohn Company LLC); the tamoxifen FDA label on DailyMed (effective December 18, 2025, Actavis Pharma, Inc.).

What does the medroxyprogesterone label say about tamoxifen?

Medroxyprogesterone's label (effective June 29, 2026) and its 2 other brand-application labels do not name tamoxifen in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Provera), NDA011839 (Pfizer), as published by Pharmacia & Upjohn Company LLC, effective June 29, 2026 (SPL set a586be28-96af-4fed-a13f-9b94fd4c7405), via openFDA; the full label on DailyMed

What does the tamoxifen label say about medroxyprogesterone?

Tamoxifen label, drug interactions

Medroxyprogesterone reduces plasma concentrations of N-desmethyl, but not tamoxifen.

Source: FDA drug label (Tamoxifen Citrate), Actavis Pharma, Inc., effective December 18, 2025 (SPL set 9b8a4211-120f-4981-ad69-928accb97637), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

21Medroxyprogesterone generic labelers
10Tamoxifen generic labelers
MedroxyprogesteroneTamoxifen
Labeled forBirth control, PainBreast cancer
Boxed warningYesYes
Pharmacy cost (NADAC)$22.85 per mL 150 mg/mL$0.277 per tablet 20 mg tablet
Shortage nowA presentation being discontinuedNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?